South Korea · Delayed Price · Currency is KRW HLB Pep Company Description
HLB Pep Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally.
It offers GMP, generic, custom, and catalog peptides, as well as offers other services. The company develops AGM-130, which is in Phase I for the treatment of triple negative breast cancer.
In addition, its pre-clinical products include AGM-331 targeted for anti-cancer therapy; AGM-380 indicated for the treatment of viral infection; and AGM-290 indicated for the treatment of infections caused by multidrug resistant bacteria.
In addition, it is involved in the development of AGM-212 indicated for the treatment of Type 2 Diabetes; AGM-217 indicated for the treatment of Type 2 diabetes and obesity; and AGM-260 indicated for the treatment of Ulcerative colitis.
The company was formerly known as Anygen Co., Ltd. and changed its name to HLB Pep Co., Ltd. in April 2025.
The company was founded in 2000 and is headquartered in Gwangju-si, South Korea.
| Country | South Korea |
| Founded | 2000 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Jae Il Kim |
Contact Details
Address: Gwangju Technopark Gwangju, 61008 South Korea | |
| Phone | 82 6 2714 1166 |
| Website | hlbpep.co.kr |
Stock Details
| Ticker Symbol | 196300 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jae Il Kim | Chief Executive Officer |